-
Professor Pu Xiaoyong: Guidelines are empowered, far and stable, CUA and CSCO jointly create a new pattern of prostate cancer diagnosis and treatment
Time of Update: 2023-01-06
"An "Medicine" Leye" is a humanistic case collection project cooperated by Beijing Chen Jumei Public Welfare Foundation and Yimaitong. The series of interviews with urologists will focus on the field
-
Science Bulletin CCIN mutations cause teratospermia and male infertility
Time of Update: 2023-01-06
CCIN mutation leading to sperm head malformation and male infertilityStarting from clinical male infertility cases, this study identifies new pathogenic gene mutations and elucidates the relevant mechanisms through basic research, and explores corresponding treatment strategies, providing important clues for genetic counseling and assisted reproduction treatment in clinical male infertility cases.
-
Research Frontier| Does Age Affect the Prognosis of Patients with Upper Urothelial Cancer after RNU Surgery?
Time of Update: 2023-01-06
Figure 1 OS data of patients under different groupsBased on the results of multivariate COX regression analysis (Table 2), the investigators found no significant correlation between sex, smoking history, ASA grade, CCI, and RNU and overall survival, and the performance trend was consistent between the two age groups.
-
Research Frontier| Does Age Affect the Prognosis of Patients with Upper Urothelial Cancer after RNU Surgery?
Time of Update: 2023-01-06
Figure 1 OS data of patients under different groupsBased on the results of multivariate COX regression analysis (Table 2), the investigators found no significant correlation between sex, smoking history, ASA grade, CCI, and RNU and overall survival, and the performance trend was consistent between the two age groups.
-
The 16th Filipino Salon invites you to share the academic feast
Time of Update: 2023-01-06
Friends, new wonderful. On November 5, 2022, the 16th "Filipino Salon" hosted by Ipsen China was successfully held online. This conference invited several authoritative experts to gather online, close
-
How can "evidence-based medicine" improve symptoms related to ureteral stent tubes? Complete ureteral stent placement may be a better solution
Time of Update: 2023-01-06
Study designBased on the Systematic Review and Meta-Analysis Priority Report Entry (PRISMA) statement, the investigators used the following subject terms ((complete intraureteral stent) OR (suture stent)) AND (symptom OR pain) AND (randomized OR randomised) for PubMed, Embase, Web of A systematic and comprehensive search of relevant English literature published before December 2021 in the three databases of Science was conducted.
-
2022 CSCO | Professor Sheng Xinan: The ice-breaking operation is underway, and the era of immunoprecision treatment for urothelial carcinoma will finally come
Time of Update: 2023-01-06
Professor Sheng Xinan:In terms of postoperative adjuvant treatment for urothelial carcinoma, the 2022 version of the CSCO guidelines for urothelial carcinoma has basically no major changes compared with the 2021 version, and we have adjusted and sorted out the adjuvant treatment part of upper urothelial carcinoma (UTUC), but the essence of the guidelines remains unchanged.
-
Research Frontiers Biochemical recurrence time as a prognostic indicator for salvage radiotherapy in prostate cancer patients
Time of Update: 2023-01-06
Therefore, the investigators hypothesized that sBCR in patients over a short period of time was associated with poor tumor control, and validated it as a predictor of prostate-specific death in patients who underwent sRT after failed radical prostatectomy.
-
Professor Pu Xiaoyong: Guidelines are empowered, far and stable, CUA and CSCO jointly create a new pattern of prostate cancer diagnosis and treatment
Time of Update: 2023-01-06
"An "Medicine" Leye" is a humanistic case collection project cooperated by Beijing Chen Jumei Public Welfare Foundation and Yimaitong. The series of interviews with urologists will focus on the field
-
The 2022 SUO PURE-01 trial data has been updated, and MIBC neoadjuvant immunotherapy has added good results
Time of Update: 2023-01-01
Image from SUO officialAbstract number: Poster #232：Three year-survival outcomes after neoadjuvant pembrolizumab and radical cystectomy: final results from the PURE-01 studyIntroduction to the studyThe PURE-01 study showed new hope for survival outcomes in patients with muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab prior to radical cystectomy (RC).
-
SUO 2022 Progress in Phase III trial for novel molecular imaging diagnosis of prostate cancer announced
Time of Update: 2023-01-01
3 PET Diagnostic Performance and Safety in Newly Diagnosed Prostate Cancer Patients: Phase 3 Prospective Multicenter Study Results (LIGHTHOUSE)First author by Brian F.
3 PET Diagnostic Performance and Safety in Newly Diagnosed Prostate Cancer Patients: Phase 3 Prospective Multicenter Study Results (LIGHTHOUSE)First author by Brian F.
-
2022 CSCO | Professor Yao Xin: Based on the international perspective and focusing on Chinese characteristics, the diagnosis and treatment of prostate cancer in China is moving to a new height
Time of Update: 2023-01-01
We look forward to the clinical research and innovation results shared at this CSCO Annual Meeting to bring more inspiration to Chinese clinicians and further promote the comprehensive development of prostate cancer diagnosis and treatment!"Editor: Gardenia Reviewed: Rudolf Executive: RudolfThis platform is designed to deliver more medical information to healthcare professionals.
-
2022 CSCO| Professor Zeng Hao: Talking about "nuclear" does not have to be discolored, and nuclear treatment of prostate cancer is safe and reliable
Time of Update: 2023-01-01
prefaceThe 25th National Congress of Clinical Oncology and the 2022 CSCO Annual Conference were held in Beijing, Jinan and Harbin from November 5 to 12 in the form of a combination of offline and onli
-
Professor Yu Wei: "Fine" Selection: Molecular Typing of Advanced Urothelial Carcinoma vs. Treatment Decisions
Time of Update: 2023-01-01
Fig. 1 EAU guidelines recommend advanced UC treatment, it can be seen that platinum-containing chemotherapy is still the standard treatment choice for advanced UC, and with the application of new therapeutic drugs such as immune checkpoint inhibitors, erdatinib and ADC drugs, how to optimize the treatment options of advanced UC is an urgent clinical problem Among them, molecular typing based on biomarkers is one of the exploration directions to guide clinical drug decision-making.
-
Courier Novartis' Phase 3 trial of targeted therapy for prostate cancer has reached the primary endpoint, and the regulatory application is about to be submitted
Time of Update: 2023-01-01
▎WuXi AppTec content team editorNovartis today announced positive results in its Phase 3 trial of its targeted radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in the treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitors (ARPIs).
-
Heavy release: China's large sample of LHRH agonist sustained-release implant prostate cancer real-world research data revealed!
Time of Update: 2023-01-01
The 2022 Asian International Urological Association Annual Meeting (UAA) and the Chinese Society of Clinical Oncology (CSCO) Annual Meeting presented a study evaluating the efficacy and safety of goserelin acetate in real-world prostate cancer patients in China [1,2].
-
SUO 2022 | progress of phase III trial for novel molecular imaging diagnosis of prostate cancer announced
Time of Update: 2023-01-01
3 PET Diagnostic Performance and Safety in Newly Diagnosed Prostate Cancer Patients: Phase 3 Prospective Multicenter Study Results (LIGHTHOUSE)First author by Brian F.
3 PET Diagnostic Performance and Safety in Newly Diagnosed Prostate Cancer Patients: Phase 3 Prospective Multicenter Study Results (LIGHTHOUSE)First author by Brian F.
-
Professor Ye Lifu: In the era of group "heroes" fighting for hegemony, how CRPC diagnosis and treatment can achieve another breakthrough
Time of Update: 2023-01-01
"An "Medicine" Leye" is a humanistic case collection project cooperated by Beijing Chen Jumei Public Welfare Foundation and Yimaitong. The series of interviews with urologists will focus on the field
-
Practice prostate case sharing: homeopathic emergence, abiraterone acetate changes the treatment pattern of patients with metastatic castration-resistant prostate cancer
Time of Update: 2023-01-01
Metastatic prostate cancer seriously affects the survival prognosis of patients, in European and American populations, metastatic prostate cancer accounts for only 5%~6% of new prostate cancer, while
-
PSA deep rapid decline, OS long-term "Ke" period, apatamide + ADT in the treatment of mHSPC showed extraordinary strength in classic cases
Time of Update: 2023-01-01
*For medical professionals onlyThe patient, a man with metastatic hormone-sensitive prostate cancer (mHSPC) with multiple bone metastases, achieved a deep reduction in PSA after 2 months of treatment with apatamide + androgen deprivation therapy (ADT), and the patient's PSA decreased from 216.
